FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387496734> ?p ?o ?g. }

• W4387496734 abstract "Antibody-drug conjugates (ADCs) that target human epidermal growth factor receptor 2 (HER2) are leading a new era of targeted cancer therapy. These drugs have also been associated with several fatal adverse events, such as pneumonia, interstitial lung disease, and infection. We performed a meta-analysis of randomized controlled trials (RCTs) to estimate the incidence and risk of fatal adverse events in cancer patients treated with HER2-targeted ADCs.We performed a systematic search in Embase, PubMed, Web of Science, and Scopus databases from inception to February 1, 2022, and the last search was updated to July 1, 2023. The eligible studies for inclusion in our analysis were limited to RCTs of HER2-targeted ADCs that were approved by the US Food and Drug Administration and examined on cancer patients with available data on fatal adverse events. The protocol for this study was registered in PROSPERO (No. CRD42022331627).Fifteen studies (13 RCTs) involving 7,277 patients were finally included for meta-analysis. Of these patients, 4,246 received HER2-targeted ADCs and 3,481 received the control treatment. The data were combined using Bayesian hierarchical modeling, which allowed for the estimation of the mean incidence of fatal adverse events to be 0.78% (95% CrI: 0.28-1.37%, τ = 0.006) for the patients treated with HER2-targeted ADCs. The relative risk was 0.80 (95% CrI, 0.5-1.26, τ = 0.17) compared to control patients. Among 43 reported deaths caused by HER2-targeted ADCs, the most common fatal adverse event was respiratory toxicity, including pneumonia, pneumonitis, and interstitial lung disease. On subgroup analysis, no difference in the risk of fatal adverse events was found between different HER2-targeted ADCs or cancer types.Our findings suggest that the risk of fatal adverse events with HER2-targeted ADCs may be lower compared to standard control therapies in cancer patients, and there is no significant difference in risk observed between different HER2-targeted ADCs or cancer types. However, the most common fatal adverse event was respiratory toxicity, suggesting that cancer patients who use the above drugs should strengthen respiratory system monitoring and take preventive measures in some severe cases." @default.
• W4387496734 created "2023-10-11" @default.
• W4387496734 creator A5005901099 @default.
• W4387496734 creator A5025856188 @default.
• W4387496734 creator A5033955686 @default.
• W4387496734 creator A5038347628 @default.
• W4387496734 creator A5069299695 @default.
• W4387496734 creator A5074734978 @default.
• W4387496734 creator A5079028856 @default.
• W4387496734 date "2023-10-10" @default.
• W4387496734 modified "2023-10-14" @default.
• W4387496734 title "Incidence and risk of fatal adverse events in cancer patients treated with HER2-targeted antibody-drug conjugates: a systematic review and meta-analysis of randomized controlled trials" @default.
• W4387496734 cites W1548668976 @default.
• W4387496734 cites W1976203623 @default.
• W4387496734 cites W2005274511 @default.
• W4387496734 cites W2120627364 @default.
• W4387496734 cites W2136527721 @default.
• W4387496734 cites W2159967578 @default.
• W4387496734 cites W2161374186 @default.
• W4387496734 cites W2165593156 @default.
• W4387496734 cites W2169205464 @default.
• W4387496734 cites W2204638621 @default.
• W4387496734 cites W2292132270 @default.
• W4387496734 cites W2598685895 @default.
• W4387496734 cites W2614773797 @default.
• W4387496734 cites W2902218997 @default.
• W4387496734 cites W2940945106 @default.
• W4387496734 cites W2958119318 @default.
• W4387496734 cites W2970684805 @default.
• W4387496734 cites W2981452012 @default.
• W4387496734 cites W3024263082 @default.
• W4387496734 cites W3037873371 @default.
• W4387496734 cites W3088588360 @default.
• W4387496734 cites W3147820834 @default.
• W4387496734 cites W3159805754 @default.
• W4387496734 cites W3165177412 @default.
• W4387496734 cites W3169329995 @default.
• W4387496734 cites W3181209874 @default.
• W4387496734 cites W3201219318 @default.
• W4387496734 cites W3217007959 @default.
• W4387496734 cites W4205599809 @default.
• W4387496734 cites W4220847494 @default.
• W4387496734 cites W4226051140 @default.
• W4387496734 cites W4281640394 @default.
• W4387496734 cites W4294379321 @default.
• W4387496734 cites W4308766741 @default.
• W4387496734 cites W4309514734 @default.
• W4387496734 cites W4313254453 @default.
• W4387496734 cites W4317932204 @default.
• W4387496734 doi "https://doi.org/10.1186/s12885-023-11250-1" @default.
• W4387496734 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37817092" @default.
• W4387496734 hasPublicationYear "2023" @default.
• W4387496734 type Work @default.
• W4387496734 citedByCount "0" @default.
• W4387496734 crossrefType "journal-article" @default.
• W4387496734 hasAuthorship W4387496734A5005901099 @default.
• W4387496734 hasAuthorship W4387496734A5025856188 @default.
• W4387496734 hasAuthorship W4387496734A5033955686 @default.
• W4387496734 hasAuthorship W4387496734A5038347628 @default.
• W4387496734 hasAuthorship W4387496734A5069299695 @default.
• W4387496734 hasAuthorship W4387496734A5074734978 @default.
• W4387496734 hasAuthorship W4387496734A5079028856 @default.
• W4387496734 hasBestOaLocation W43874967341 @default.
• W4387496734 hasConcept C120665830 @default.
• W4387496734 hasConcept C121332964 @default.
• W4387496734 hasConcept C121608353 @default.
• W4387496734 hasConcept C126322002 @default.
• W4387496734 hasConcept C143998085 @default.
• W4387496734 hasConcept C197934379 @default.
• W4387496734 hasConcept C2776256026 @default.
• W4387496734 hasConcept C61511704 @default.
• W4387496734 hasConcept C71924100 @default.
• W4387496734 hasConcept C95190672 @default.
• W4387496734 hasConceptScore W4387496734C120665830 @default.
• W4387496734 hasConceptScore W4387496734C121332964 @default.
• W4387496734 hasConceptScore W4387496734C121608353 @default.
• W4387496734 hasConceptScore W4387496734C126322002 @default.
• W4387496734 hasConceptScore W4387496734C143998085 @default.
• W4387496734 hasConceptScore W4387496734C197934379 @default.
• W4387496734 hasConceptScore W4387496734C2776256026 @default.
• W4387496734 hasConceptScore W4387496734C61511704 @default.
• W4387496734 hasConceptScore W4387496734C71924100 @default.
• W4387496734 hasConceptScore W4387496734C95190672 @default.
• W4387496734 hasFunder F4320321001 @default.
• W4387496734 hasIssue "1" @default.
• W4387496734 hasLocation W43874967341 @default.
• W4387496734 hasLocation W43874967342 @default.
• W4387496734 hasOpenAccess W4387496734 @default.
• W4387496734 hasPrimaryLocation W43874967341 @default.
• W4387496734 hasRelatedWork W2064573700 @default.
• W4387496734 hasRelatedWork W2417314287 @default.
• W4387496734 hasRelatedWork W2554284703 @default.
• W4387496734 hasRelatedWork W2611523470 @default.
• W4387496734 hasRelatedWork W2981696006 @default.
• W4387496734 hasRelatedWork W3210678099 @default.
• W4387496734 hasRelatedWork W4200125571 @default.
• W4387496734 hasRelatedWork W4246615163 @default.
• W4387496734 hasRelatedWork W4360943417 @default.
• W4387496734 hasRelatedWork W4386361997 @default.
• W4387496734 hasVolume "23" @default.

• next